CN Patent

CN107001283B — Flt3受体拮抗剂

Assigned to Centre National de la Recherche Scientifique CNRS · Expires 2021-05-25 · 5y expired

What this patent protects

本发明涉及通式(1)的新型FLT3受体拮抗剂。该化合物用于治疗或预防疼痛病症、癌症和自身免疫性疾病。

USPTO Abstract

本发明涉及通式(1)的新型FLT3受体拮抗剂。该化合物用于治疗或预防疼痛病症、癌症和自身免疫性疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN107001283B
Jurisdiction
CN
Classification
—
Expires
2021-05-25
Drug substance claim
No
Drug product claim
No
Assignee
Centre National de la Recherche Scientifique CNRS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.